Portal de investigación
Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Shortt, Jake
- Tan, Shuh Ying
- Ng, Teng Fong
- Fong, Chun Yew
- Cannell, Paul
- Rajagopal, Rajeev
- Leitch, Sophia
- Tan, Peter T.
- Ramanathan, Sundra
- Gasiorowski, Robin
- Lenton, Douglas Stuart
- Teh, Tse-Chieh
- Perez-Simon, Jose Antonio
- Grove, Carolyn
- Huang, Xiaojun
- DiNardo, Courtney D.
- Naidu, Katherine
- Pariseau, Joseph
- Cheng, Si
- Liu, Yu
- Co, Melannie
- Chan, Wai Y.
- Guo, Haiyi
- Wei, Andrew H.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 3329-3332
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Shortt,J,Montesinos,P,Tan,SY,Ng,TF,Fong,CY,Cannell,P,Rajagopal,R et al. Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML). 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2022 p.p. 3329-3332.